Patents by Inventor Verena Gafner

Verena Gafner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8455625
    Abstract: Conjugate for targeting therapeutic or diagnostic agent or drug to cells or tissues in a body, e.g. areas of neoplastic growth or angiogenesis. Use of conjugate for in vivo diagnosis or therapy e.g. inhibiting tumor growth or metastasis, inhibiting angiogenesis and/or treating cancer. Conjugate comprises therapeutic or diagnostic agent as oligomeric protein e.g. heterodimeric protein, wherein first and second subunits of protein are each conjugated to a specific binding member e.g. an antibody fragment such as scFv. Subunits of oligomer may be conjugated to specific binding members as fusion proteins. Conjugate may comprise IL-12 heterodimer having two subunits, each subunit fused to scFv L19 or TN11 for targeting IL-12 to extracellular matrix components associated with neoplastic growth and angiogenesis.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: June 4, 2013
    Assignee: Philogen S.p.A.
    Inventors: Dario Neri, Verena Gafner, Cornelia Halin
  • Publication number: 20090035255
    Abstract: Conjugate for targeting therapeutic or diagnostic agent or drug to cells or tissues in a body, e.g. areas of neoplastic growth or angiogenesis. Use of conjugate for in vivo diagnosis or therapy e.g. inhibiting tumour growth or metastasis, inhibiting angiogenesis and/or treating cancer. Conjugate comprises therapeutic or diagnostic agent as oligomeric protein e.g. heterodimeric protein, wherein first and second subunits of protein are each conjugated to a specific binding member e.g. an antibody fragment such as scFv. Subunits of oligomer may be conjugated to specific binding members as fusion proteins. Conjugate may comprise IL-12 heterodimer having two subunits, each subunit fused to scFv L19 or TN11 for targeting IL-12 to extracellular matrix components associated with neoplastic growth and angiogenesis.
    Type: Application
    Filed: May 3, 2006
    Publication date: February 5, 2009
    Inventors: Dario Neri, Verena Gafner, Cornelia Halin